公开(公告)号：US20140242070A1

公开(公告)日：2014-08-28

申请号：US14127017

申请日：2012-06-15

Applicant: Taranjit S. Gujral ,  Gavin MacBeath

Inventor： Taranjit S. Gujral ,  Gavin MacBeath

IPC: C07K16/28

CPC classification number: C12Q1/6883 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/2863 ,  C07K16/30 ,  C07K16/303 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C12Q2600/106 ,  C12Q2600/158

Abstract: Disclosed herein are methods of treating cancer in a subject, and methods for inhibiting growth, migration and/or invasion of a cancer cell in the subject, comprising administering to the subject a therapeutically effective amount of an antibody or antigen binding fragment thereof that downmodulates Fzd2. The antibody may specifically bind Fzd2, and may promote internalization of the Fzd2 receptor by the cancer cells and/or prevent ligand binding to Fzd2. Specific antibodies, and also specific portions of the Fzd2 molecule for antibody binding are disclosed. In one embodiment the antibody specifically binds to the epitope HGAEQICVGQNHSEDGAPAL (SEQ ID NO: 1). Specific cancers (e.g. late stage hepatocellular carcinoma), intended for treatment are provided, and include cancers that exhibit overexpression of Fzd2, and/or Wnt5a.

Abstract translation: 本文公开了治疗受试者的癌症的方法以及用于抑制受试者中癌细胞的生长，迁移和/或侵袭的方法，包括向受试者施用治疗有效量的下调Fzd2的抗体或其抗原结合片段 。 抗体可以特异性结合Fzd2，并且可以促进癌细胞对Fzd2受体的内化和/或阻止配体结合Fzd2。 公开了特异性抗体以及用于抗体结合的Fzd2分子的特定部分。 在一个实施方案中，抗体特异性结合表位HGAEQICVGQNHSEDGAPAL（SEQ ID NO：1）。 提供旨在治疗的特异性癌症（例如晚期肝细胞癌），包括表现出过度表达Fzd2和/或Wnt5a的癌症。

公开(公告)号：US07323346B2

公开(公告)日：2008-01-29

申请号：US10920116

申请日：2004-08-16

Applicant: Ravi I. Thadhani ,  Myles S. Wolf ,  Tanya Lynn Knickerbocker ,  Gavin MacBeath

Inventor： Ravi I. Thadhani ,  Myles S. Wolf ,  Tanya Lynn Knickerbocker ,  Gavin MacBeath

IPC: G01N33/543 ,  G01N33/53

CPC classification number: G01N33/689 ,  G01N2333/505 ,  G01N2333/52 ,  G01N2333/525 ,  G01N2333/53 ,  G01N2333/54 ,  G01N2333/555 ,  G01N2333/5756 ,  G01N2333/61 ,  G01N2800/368 ,  G06F19/20 ,  Y10S436/811

Abstract: The invention relates to methods and compositions for identifying pregnant subjects having, or predisposed to having, gestational diabetes, preeclampsia, and gestational hypertension. The methods are applicable to urine and/or blood samples and can be conducted prior to the third trimester of pregnancy, and as early as the first trimester.

Abstract translation: 本发明涉及用于鉴定具有妊娠糖尿病，先兆子痫和妊娠高血压患有或倾向于具有妊娠糖尿病，先兆子痫和妊娠高血压的怀孕受试者的方法和组合 这些方法适用于尿液和/或血液样品，可以在妊娠前三个月，早在妊娠前期进行。

公开(公告)号：US07063979B2

公开(公告)日：2006-06-20

申请号：US10171128

申请日：2002-06-13

Applicant: Gavin MacBeath ,  Jennipher Grudzien

Inventor： Gavin MacBeath ,  Jennipher Grudzien

IPC: C12M1/18 ,  B01L3/00

CPC classification number: B01L3/5085 ,  B01J19/0046 ,  B01J2219/00315 ,  B01J2219/00317 ,  B01J2219/00364 ,  B01J2219/00385 ,  B01J2219/00497 ,  B01J2219/00527 ,  B01J2219/00533 ,  B01J2219/00536 ,  B01J2219/00576 ,  B01J2219/00585 ,  B01J2219/00596 ,  B01J2219/00605 ,  B01J2219/0061 ,  B01J2219/00612 ,  B01J2219/00621 ,  B01J2219/00626 ,  B01J2219/00628 ,  B01J2219/0063 ,  B01J2219/00637 ,  B01J2219/00659 ,  B01J2219/00673 ,  B01J2219/00677 ,  B01J2219/00691 ,  B01J2219/00707 ,  B01J2219/00722 ,  B01J2219/00725 ,  B01J2219/00731 ,  B01L2200/0689 ,  B01L2200/12 ,  B01L2300/0636 ,  B01L2300/0829 ,  B01L2300/0851 ,  C40B40/06 ,  C40B40/10 ,  C40B40/12 ,  C40B60/14

Abstract: The invention describes a process for preparing a microtiter-microarray device that includes a bottomless microtiter plate attached to the first side of one or more substrates with microarrays of materials attached thereto. The microtiter plate and the one or more substrates are attached through one or more gaskets. Preferably, the microtiter plate is attached to one face of the one or more gaskets by an irreversible water-tight seal, and the first side of the one or more substrates is attached to the opposite face of the one or more gaskets by a reversible, water-tight seal.